Zeta CA IX Antibody. Zeta’s recombinant rabbit antibody recognizes CA IX, which may help investigate carcinomas of proximal nephrogenic differentiation, especially those showing tubular differentiation. Zeta’s CA IX antibody recognizes a glycoprotein of ~200kDa, identified as the transmembrane protein Carbonic Anhydrase IX (gp200), which is upregulated in hypoxic environments including necrosis. In the normal kidney, CA IX is localized along the brush border of the pars convoluta and pars recta segments of the proximal tubule and focally along the luminal surface of Bowman’s capsule adjoining the outgoing proximal tubule. CA IX is expressed by 93% of primary and 84% of metastatic renal cell carcinomas. CA IX is primarily used in differentiating kidney tumors but not specific to renal primary tumors and show strong membranous staining in mesothelioma, mesothelial lesions and mesothelium.
CA IX can be used to differentiate renal cell carcinoma (RCC) subtypes including clear cell RCC (diffuse) versus papillary RCC (focal) versus clear cell papillary RCC (diffuse, cup-like) versus chromophobe RCC (negative) versus Xp11 translocation RCC (negative or focal). Additionally, CA IX can aid in discrimination of select meningioma subtypes (negative in clear cell versus positive in microcystic and angiomatous).
Zeta Corporation is a leader in recombinant monoclonal IVD antibodies for immunohistochemistry (IHC) offering 400+ tumor and tissue specific relevant products developed by a pathologist for pathologists. Visit Precision Recombinant Antibodies – IVD Antibodies – About Zeta Corporation (zeta-corp.com) to learn more about Zeta Corporation.